MLND News and Press, Millendo Therapeutics From 03/29/19

Millendo Therapeutics (NASDAQ: MLND ): FY GAAP EPS of -$17.58. More news on: Millendo Therapeutics, Inc., Earnings news and commentary, , Read more ...

--Initiated ZEPHYR, a pivotal Phase 2b/3 clinical study of livoletide for patients with Prader-Willi syndrome (PWS), in 1Q19-- --Topline data from Phase 2b Portion of ZEPHYR and Phase 2b clinical study of nevanimibe for classic congenital adrenal hyperplasia (CAH) expected in 1H20-- ...

Top-line Phase 2b results are expected in 1H 2020 and may support an NDA submission for livoletide Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that it has initiated ...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that its clinical candidates, livoletide (AZP-531) and nevanimibe (ATR-101), will be featured in three poster presentations at E...

It’s still very early, but Neurocrine Biosciences ( NBIX ) might have another compelling, largely underrated, drug in NBI-74788 for congenital adrenal hyperplasia (or CAH). Although Ph IIa data does little more than work to establish proof of concept at this point, I do believe it...

The following slide deck was published by Millendo Therapeutics, Inc. in conjunction with this Read more ...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences....

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8 th Annual SVB Leerink Global Healthcar...

Millendo Therapeutics, Inc. (“Millendo” or the “Company”) (NASDAQ: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that on January 28, 2019, the Compensation Committee of the Board of D...